Evidence map›Paper›PMID 36906640›Full record

ArticleCommunications biology2023

CD83 expression characterizes precursor exhausted T cell population.

Zhiwen Wu, Toshiaki Yoshikawa, Satoshi Inoue, Yusuke Ito, Hitomi Kasuya, Takahiro Nakashima, Haosong Zhang, Saki Kotaka, Waki Hosoda, Shiro Suzuki and 1 more

Open access · goldFull text read
In one paragraph

Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Clonal CD8Nature immunology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Zhiwen WuDivision of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
Toshiaki YoshikawaDivision of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
Satoshi InoueDivision of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
Yusuke ItoDivision of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
Hitomi KasuyaDivision of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
Takahiro NakashimaDivision of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
Haosong ZhangDivision of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
Saki KotakaDepartment of Gynecologic Oncology, Aichi Cancer Center, Nagoya, Japan.
Waki HosodaDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
Shiro SuzukiDepartment of Gynecologic Oncology, Aichi Cancer Center, Nagoya, Japan.
Yuki KagoyaDivision of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan. ykagoya@keio.jp.ORCID 0000-0002-6216-6730
Aichi Cancer Center · JPInstitute for Advanced Medical Research · USKeio University · JPNagoya City University · JP

Funding

MEXT | Japan Science and Technology Agency (JST) JPMJFR2060MEXT | Japan Society for the Promotion of Science (JSPS) 19K09297MEXT | Japan Society for the Promotion of Science (JSPS) 20H03543MEXT | Japan Society for the Promotion of Science (JSPS) 20K22793
6 · The paper itself

Abstract

T cell exhaustion is a main obstacle against effective cancer immunotherapy. Exhausted T cells include a subpopulation that maintains proliferative capacity, referred to as precursor exhausted T cells (T

Indexed as

NeoplasmsT-Lymphocyte SubsetsHumansImmunotherapyLymphocytes, Tumor-InfiltratingReceptors, CCR7Receptors, CCR7

Identifiers

PMID36906640
PMCPMC10008643
OpenAlexW4323971920

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read22
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.